The development of tissue-engineered skin (Apligraf; Organogenesis Inc, Canton, Mass), which has been approved for venous leg ulcers and diabetic neuropathic foot ulcers, has offered a new option for patients with chronic wounds.1 How tissue-engineered skin heals chronic wounds is under investigation, but it appears to work primarily as a stimulus to healing, likely through the production of various cytokines.